These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27379819)

  • 21. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bupropion for the treatment of methamphetamine dependence.
    Elkashef AM; Rawson RA; Anderson AL; Li SH; Holmes T; Smith EV; Chiang N; Kahn R; Vocci F; Ling W; Pearce VJ; McCann M; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Weis D
    Neuropsychopharmacology; 2008 Apr; 33(5):1162-70. PubMed ID: 17581531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
    Krupitsky EM; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):49-56. PubMed ID: 25591636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
    Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash.
    Wright FL; Rodgers RJ
    Psychopharmacology (Berl); 2013 Jul; 228(2):291-307. PubMed ID: 23455599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.
    Crits-Christoph P; Markell HM; Gibbons MB; Gallop R; Lundy C; Stringer M; Gastfriend DR
    J Subst Abuse Treat; 2016 Nov; 70():50-57. PubMed ID: 27692188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.
    Jarvis BP; DeFulio A; Long L; Holtyn AF; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():56-60. PubMed ID: 28161142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.
    Coffin PO; Santos GM; Hern J; Vittinghoff E; Santos D; Matheson T; Colfax G; Batki SL
    Addiction; 2018 Feb; 113(2):268-278. PubMed ID: 28734107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
    Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
    Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.
    Crits-Christoph P; Lundy C; Stringer M; Gallop R; Gastfriend DR
    J Subst Abuse Treat; 2015 Sep; 56():54-60. PubMed ID: 25841704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
    Lee JD; Grossman E; Huben L; Manseau M; McNeely J; Rotrosen J; Stevens D; Gourevitch MN
    J Subst Abuse Treat; 2012 Dec; 43(4):458-62. PubMed ID: 22985676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
    Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
    Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
    Lapham SC; McMillan GP
    J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
    Mitchell MC; Memisoglu A; Silverman BL
    J Stud Alcohol Drugs; 2012 Nov; 73(6):991-7. PubMed ID: 23036218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.